Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Osimertinib (TAGRISSO) (ROSY-T)
← catalyst calendarNCT05629234 · readout in 186 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With Parexel.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
37estimated
Sites
27
Countries
China, France, Japan +5
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-05-08 | actual | When the study began enrolling |
| Primary completion | 2027-02-22 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-02-22 | estimated | The whole study's end, after follow-up |
| First posted | 2022-11-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-09 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Cancer
Intervention
- Drug: Osimertinib — also filed as TAGRISSO
Primary outcome
what the primary-completion date above is the date OFNumber of patients with Serious Adverse Events (SAEs), and Adverse Events of Special Interest (AESIs)
measured Until 90 days after the last dose of study treatment
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed